
UroGen Pharma (URGN) Stock Forecast & Price Target
UroGen Pharma (URGN) Analyst Ratings
Bulls say
UroGen Pharma is supported by a rapidly improving commercial profile, led by 3Q26 Zusduri revenue of $68.0M, up 35% sequentially and above consensus, while total revenue of $89.0M was roughly in line and the company posted its first meaningful operating income of $8.3M. Launch metrics also strengthened materially, with unique prescribers rising to 662, repeat prescribers reaching about 50% of the total, and activated sites increasing to 1,538, suggesting deeper adoption and expanding recurring use. The outlook is further reinforced by a patent extending coverage into July 2044, FDA acceptance of UGN-103 with a June 14, 2027 PDUFA date, and a pipeline that includes LONGVIEW-HR in 4Q26 and UGN-501 in 4Q26, even as lower Jelmyto guidance to about $90M reflects near-term noise rather than structural weakness.
Bears say
UroGen Pharma is vulnerable to multiple fundamental risks because its valuation depends heavily on a narrow commercial base of two approved products, Jelmyto and Zusduri, both sold principally in the United States, leaving it exposed to any slowdown in adoption or reimbursement. As a clinical-stage biotechnology firm, it also faces meaningful R&D and regulatory uncertainty, and any setbacks in development or approval could reduce confidence in its RTGel platform and limit future growth opportunities. The negative outlook is further supported by the possibility of new competitors, lower-than-expected product sales, and dilutive financing, any of which could pressure earnings quality and shareholder value.
This aggregate rating is based on analysts' research of UroGen Pharma and is not a guaranteed prediction by Public.com or investment advice.
UroGen Pharma (URGN) Analyst Forecast & Price Prediction
Start investing in UroGen Pharma (URGN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About UroGen Pharma (URGN) Forecast
UroGen Pharma (URGN) Analyst Forecast & Price Prediction
Start investing in UroGen Pharma (URGN)
Order type
Buy in
Order amount
Est. shares
0 shares